The challenges in diagnosis and treatment of multiple myeloma in Latin America: a multinational survey and proposal for improvement

Camila Peña; Breno Moreno De Gusmão; Eloísa Riva; Alana Von Glasenapp; Dorotea Beatriz Eugenia Fantl; Rodrigo Meneces Bustillo; Aline Ramirez; David Gómez‐Almaguer; Julio Fernández-Águila; Manolo Antônio Granja; Esmedaly Romero; Jule F Vasquez; Humberto Martínez‐Cordero; Ariel Corzo; Rafael Cunha; Fernanda Lemos Moura; Maria Victoria Mateos · JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY (2026) · DOI: 10.46765/2675-374x.2025v7n1e346

Resumen

Multiple myeloma (MM) is a malignant hematologic disease marked by the abnormal growth of plasma cells, resulting in serious complications such as bone fractures, hypercalcemia, renal dysfunction, and anemia. It represents the second most frequent hematologic malignancy and is usually diagnosed at an advanced stage in Latin America. A multinational survey included 16 experts from 11 Latin American countries to share their experiences in myeloma healthcare, discuss existing gaps, and propose solutions. The public healthcare system struggles with slow diagnosis and treatment access, particularly in rural areas. The private system faces challenges related to insurance coverage and costs. A significant gap exists between the need for diagnostic tests and their availability. Access to new cancer treatments is hindered by inadequate public policies, high drug costs, and inconsistent approval processes. A comprehensive approach for improving MM management in Latin America is crucial, emphasizing training, access, stakeholder engagement, data enhancement, and financial resources.